Stocks and Investing
Stocks and Investing
Thu, April 21, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Jayson Bedford Maintained (ABT) at Buy with Decreased Target to $135 on, Apr 21st, 2022
Jayson Bedford of Raymond James, Maintained "Abbott Laboratories" (ABT) at Buy with Decreased Target from $143 to $135 on, Apr 21st, 2022.
Jayson has made no other calls on ABT in the last 4 months.
There are 7 other peers that have a rating on ABT. Out of the 7 peers that are also analyzing ABT, 0 agree with Jayson's Rating of Hold.
These are the ratings of the 7 analyists that currently disagree with Jayson
- Vijay Kumar of "Evercore ISI Group" Maintained at Buy and Held Target at $114 on, Sunday, April 10th, 2022
- Larry Biegelsen of "Wells Fargo" Maintained at Buy with Decreased Target to $150 on, Friday, April 8th, 2022
- Travis Steed of "B of A Securities" Initiated at Strong Buy and Held Target at $140 on, Wednesday, March 2nd, 2022
- Cecilia Furlong of "Morgan Stanley" Maintained at Buy with Decreased Target to $151 on, Thursday, January 27th, 2022
- Matt Miksic of "Credit Suisse" Maintained at Buy with Increased Target to $139 on, Thursday, January 27th, 2022
- Matthew Taylor of "UBS" Maintained at Strong Buy with Increased Target to $142 on, Thursday, January 27th, 2022
- Robbie Marcus of "JP Morgan" Maintained at Buy and Held Target at $125 on, Saturday, January 22nd, 2022
Contributing Sources